---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023344"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-05-15T12:00:31+00:00"
generated_at: "2026-05-15T12:06:28.479496+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Indaptus Therapeutics Q1 2026 net loss $2.5M; cash burn concerns with only $1.5M left

## Summary
- Q1 2026 net loss narrowed to $2.5M vs $4.5M YoY; loss per share $0.23 (post reverse split).
- Cash and equivalents fell to $1.5M from $8.5M at Dec 2025; company needs to raise additional capital.
- R&D expenses dropped 82% to $0.5M due to Phase 1 clinical cost decrease and headcount reductions.
- Executive management transition underway; reassessing development priorities and Decoy platform.
- Preferred stock conversion completed during Q1 2026; all Series AA and AAA shares converted to common.

## SEC filing metadata
- accession: 0001493152-26-023344
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-05-15T12:00:31+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/0001493152-26-023344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226023344/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023344
- JSON: https://secwatch.observer/filing/0001493152-26-023344.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023344.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.